

BIOCON GROUP

FACT SHEET

March - 2017

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Cr)

	March 31, 2017	March 31, 2016
ASSETS		
Non-current assets		
(a) Property, plant and equipment	3,553	1,681
(b) Capital work-in-progress	533	2,060
(c) Investment property	1	1
(d) Goodwill	26	26
(e) Other intangible assets	46	41
(f) Intangible assets under development	306	180
(g) Investments in associates and a joint venture	42	26
(h) Financial assets	-	-
Investments	146	-
Derivative assets	109	61
Other financial assets	20	26
(i) Income tax asset, net	90	85
(j) Deferred tax asset, net	197	72
(k) Other non-current assets	278	229
	5,347	4,488
Current assets		
(a) Inventories	635	542
(b) Financial assets		
Investments	1,065	875
Trade receivables	883	715
Cash and cash equivalents	710	761
Other bank balances	334	777
Derivative assets	106	51
Other financial assets	155	184
(c) Other current assets	159	65
	4,047	3,970
TOTAL	9,394	8,458
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	100	100
(b) Other equity	4,738	3,934
Equity attributable to equity holders of the Company	4,838	4,034
Non-controlling interest	376	266
	5,214	4,300
Non-current liabilities		
(a) Financial liabilities		
Borrowings	2,108	2,072
Derivative liability	6	19
Other financial liabilities	-	-
(b) Provisions	36	30
(c) Other non-current liabilities	352	371
	2,502	2,492
Current liabilities		
(a) Financial liabilities		
Borrowings	97	395
Trade payables	740	610
Derivative liability	6	14
Other financial liabilities	326	196
(b) Short-term provision	47	37
(c) Income tax liability, net	96	97
(d) Other current liabilities	366	317
	1,678	1,666
TOTAL	9,394	8,458

BIOCON LIMITED (CONSOLIDATED)									
PROFIT & LOSS STATEMENT									
(Rs. Cr)									
Particulars	FY 2017			FY 2016			Variance IGAAP	Variance IndAS	
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS			
INCOME									
Biocon	2,626	112	2,738	2,391	(114)	2,277	10%	20%	
Small molecules	1,503	84	1,587	1,362	25	1,387	10%	14%	
Biologics	442	16	458	351	(9)	342	26%	34%	
Branded formulations	550	(1)	549	557	(117)	440	-1%	24%	
Licensing#	131	13	144	121	(13)	108	9%	35%	
Syngene - Research Services	1,138	-	1,138	1,060	-	1,060	7%	7%	
Total Sales	3,764	112	3,876	3,451	(114)	3,337	9%	16%	
Other income	192	11	203	120	3	123	60%	65%	
TOTAL REVENUE	3,956	123	4,079	3,571	(111)	3,460	11%	18%	
EXPENDITURE									
Material & Power costs	1,566	45	1,611	1,487	(6)	1,481	5%	9%	
Staff costs	681	5	686	584	(26)	558	17%	23%	
Research & Development expenses*	267	-	267	275	(1)	274	-3%	-3%	
Other expenses	376	2	378	323	(23)	300	16%	26%	
Manufacturing, staff & other expenses	2,890	52	2,942	2,669	(56)	2,613	8%	13%	
EBITDA	1,066	71	1,137	902	(55)	847	18%	34%	
Interest & Finance charges	26	-	26	10	19	29	155%	-11%	
Depreciation & Amortisation	269	8	277	243	6	249	11%	11%	
Share of profit in JV	(16)	-	(16)	-	(22)	(22)	-	-25%	
PBT BEFORE EXCEPTIONAL ITEM	787	63	850	649	(58)	591	21%	44%	
Exceptional item, Net	-	-	-	575	(415)	160	-	-	
PBT	787	63	850	1,224	(473)	751	-36%	13%	
Taxes	127	27	154	138	(8)	130	-8%	18%	
Taxes on exceptional item	8	-	8	117	(104)	13	-	-	
NET PROFIT BEFORE MINORITY INTEREST	652	36	688	969	(361)	608	-33%	13%	
Minority interest	72	4	76	74	(16)	58	-3%	29%	
NET PROFIT FOR THE PERIOD	580	32	612	895	(345)	550	-35%	11%	
EPS Rs.	29.0		30.6	44.8		27.5			
NET PROFIT BEFORE EXCEPTIONAL ITEM	588	32	620	437	(34)	403	35%	54%	
Exceptional item, net of taxes	(8)	-	(8)	458	(311)	147			
NET PROFIT FOR THE PERIOD	580	32	612	895	(345)	550	-35%	11%	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>									
<i>* Gross Research & Development expenses</i>			402				427		

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Cr)

Particulars	Q4 - FY17			Q4 - FY16			Variance IGAAP	Variance IndAS
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS		
INCOME								
Biocon	643	10	653	655	(25)	630	-2%	4%
Small molecules	381	6	387	385	10	395	-1%	-2%
Biologics	119	-	119	115	5	120	5%	0%
Branded formulations	131	-	131	132	(27)	105	-1%	25%
Licensing#	12	4	16	23	(13)	10	-51%	50%
Syngene - Research Services	272	-	272	316	-	316	-14%	-14%
Total Sales	915	10	925	971	(25)	946	-6%	-2%
Other income	47	2	49	32	(5)	27	44%	80%
TOTAL REVENUE	962	12	974	1,003	(30)	973	-4%	0%
EXPENDITURE								
Material & Power costs	383	-	383	402	5	407	-5%	-6%
Staff costs	178	-	178	161	(7)	154	11%	16%
Research & Development expenses*	65	-	65	100	(1)	99	-35%	-35%
Other expenses	125	(8)	117	102	(10)	92	23%	27%
Manufacturing, staff & other expenses	751	(8)	743	765	(13)	752	-2%	-1%
EBITDA	211	20	231	238	(17)	221	-11%	5%
Interest & Finance charges	5	-	5	1	19	20	257%	-76%
Depreciation & Amortisation	71	2	73	63	2	65	12%	12%
Share of profit in JV	(6)	-	(6)	-	(5)	(5)	-	4%
PBT BEFORE EXCEPTIONAL ITEM	141	18	159	174	(33)	141	-19%	13%
Exceptional item, Net	-	-	-	268	-	268	-	-
PBT	141	18	159	442	(33)	409	-68%	-61%
Taxes	(9)	12	3	46	(3)	43	-119%	-94%
Taxes on exceptional item	8	-	8	12	-	12	-	-
NET PROFIT BEFORE MINORITY INTEREST	142	6	148	384	(30)	354	-63%	-58%
Minority interest	18	3	21	23	(2)	21	-22%	-2%
NET PROFIT FOR THE PERIOD	124	3	127	361	(28)	333	-66%	-62%
EPS Rs.	6.2		6.4	18.1		16.7		
NET PROFIT BEFORE EXCEPTIONAL ITEM	132	3	135	105	(28)	77	26%	75%
Exceptional item, net of taxes	(8)	-	(8)	256	-	256		
NET PROFIT FOR THE PERIOD	124	3	127	361	(28)	333	-66%	-62%

Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers

* Gross Research & Development expenses

98

152

BIOCON LIMITED (CONSOLIDATED)									
PROFIT & LOSS STATEMENT									
(Rs. Cr)									
Particulars	Q4 - FY17			Q3 - FY17			Variance IGAAP	Variance IndAS	
	IGAAP	Adj	IndAS	IGAAP	Adj	IndAS			
INCOME									
Biocon	643	10	653	705	7	712	-9%	-8%	
Small molecules	381	6	387	383	7	390	-1%	-1%	
Biologics	119	-	119	120	-	120	0%	0%	
Branded formulations	131	-	131	123	(1)	122	6%	6%	
Licensing	12	4	16	79	1	80	-85%	-80%	
Syngene - Research Services	272	-	272	317	-	317	-14%	-14%	
Total Sales	915	10	925	1,022	7	1,029	-10%	-10%	
Other income	47	2	49	59	4	63	-20%	-21%	
TOTAL REVENUE	962	12	974	1,081	11	1,092	-11%	-11%	
EXPENDITURE									
Material & Power costs	383	-	383	407	-	407	-6%	-6%	
Staff costs	178	-	178	177	2	179	0%	-1%	
Research & Development expenses*	65	-	65	85	-	85	-23%	-23%	
Other expenses	125	(8)	117	90	7	97	39%	21%	
Manufacturing, staff & other expenses	751	(8)	743	759	9	768	-1%	-3%	
EBITDA	211	20	231	322	2	324	-35%	-29%	
Interest & Finance charges	5	-	5	9	-	9	-43%	-43%	
Depreciation & Amortisation	71	2	73	69	2	71	3%	3%	
Share of profit in JV	(6)	-	(6)	(1)	-	(1)	-	588%	
PBT BEFORE EXCEPTIONAL ITEM	141	18	159	245	-	245	-42%	-35%	
Exceptional item, Net	-	-	-	-	-	-	-	-	
PBT	141	18	159	245	-	245	-43%	-35%	
Taxes	(9)	12	3	54	1	55	-116%	-95%	
Taxes on exceptional item	8	-	8	-	-	-	-	-	
NET PROFIT BEFORE MINORITY INTEREST	142	6	148	191	(1)	190	-26%	-22%	
Minority interest	18	3	21	19	-	19	-8%	7%	
NET PROFIT FOR THE PERIOD	124	3	127	172	(1)	171	-28%	-26%	
EPS Rs.	6.2		6.4	8.6		8.6			
NET PROFIT BEFORE EXCEPTIONAL ITEM	132	3	135	172	(1)	171	-23%	-21%	
Exceptional item, net of taxes	(8)	-	(8)	-	-	-			
NET PROFIT FOR THE PERIOD	124	3	127	172	(1)	171	-28%	-26%	
<i>Note: The figures are rounded off to the nearest crore, percentages are based on absolute numbers</i>									
* Gross Research & Development expenses			98				100		